Tipifarnib

Generic Name: Tipifarnib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₂Cl_₂N_₄O

CAS Number: 192185-72-1

Unique Ingredient Identifier: MAT637500A

Background: Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

Indication: Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor-positive Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: fulvestrant
Drug: tipifarnib

First Posted Date: 2004-05-19

Last Posted Date: 2018-11-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00082810

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: trastuzumab
Drug: tipifarnib

First Posted Date: 2004-04-26

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00005842

Locations: 🇺🇸
Institute for Drug Development, San Antonio, Texas, United States
🇺🇸
Brooke Army Medical Center, Fort Sam Houston, Texas, United States

R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-20

Last Posted Date: 2011-08-04

Lead Sponsor: Mayo Clinic

Registration Number: NCT00005989

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

R115777 in Treating Patients With Advanced Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

First Posted Date: 2004-04-02

Last Posted Date: 2013-12-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT00006376

Locations: 🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-03-16

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 7

Registration Number: NCT00005848

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma

Phase 1

Completed

Conditions: Untreated Childhood Brain Stem Glioma

Interventions: Radiation: radiation therapy
Drug: tipifarnib

First Posted Date: 2004-03-10

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00079339

Locations: 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States

R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: tipifarnib

First Posted Date: 2004-03-05

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00005843

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2004-02-12

Last Posted Date: 2020-04-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 18

Registration Number: NCT00077519

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: tipifarnib
Drug: capecitabine

First Posted Date: 2004-02-12

Last Posted Date: 2013-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00077363

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

Phase 2

Completed

Conditions: Childhood High-grade Cerebral Astrocytoma
Childhood Oligodendroglioma
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Medulloblastoma
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Recurrent Childhood Visual Pathway and Hypothalamic Glioma

Interventions: Drug: tipifarnib

First Posted Date: 2003-10-07

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT00070525

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy